Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
Laura A. Sena(Johns Hopkins University), Samuel R. Denmeade(Johns Hopkins University)
Cited by 44
Related Papers
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
|Prostate Cancer and Prostatic Diseases|2024|9
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
|medRxiv|2024|3
Lipid-Oxidizing B Cells Enable Successful Vaccine Response Despite Immunosuppression
|SSRN Electronic Journal|2022|2